Aligos Therapeutics reported a net loss of $15.9 million for the second quarter of 2025, compared to a net income of $5.1 million for the same period in 2024. Research and development (R&D) expenses decreased to $14.0 million from $21.1 million year-over-year. This decrease was primarily due to reduced clinical study costs following the completion of the MASH Phase 2a clinical trial, partially offset by increased spending in the chronic HBV infection program.
As of June 30, 2025, the company held $122.9 million in cash, cash equivalents, and investments. This financial position is expected to provide sufficient funding for planned operations into the second half of 2026. The company's cash runway was maintained following its recent private placement.
The company announced that the initiation of the Phase 2 B-SUPREME study of ALG-000184 is well underway, with regulatory approvals secured across multiple countries including the US, China, Canada, Taiwan, UK, New Zealand, and Moldova. Dosing in this pivotal study is expected to commence in the coming weeks.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.